**Core tip:** ^18^F-labelled fluorodeoxyglucose (^18^F-FDG) uptake overlaps significantly between malignant and benign prostatic conditions. In a cohort of nearly 3000 patients over a 5-year period, the reporting of incidental elevated prostatic ^18^F-FDG uptake did not affect subsequent clinical management or patient outcomes.

INTRODUCTION
============

Positron emission tomography of ^18^F-labelled fluorodeoxyglucose uptake combined with computed tomography (^18^F-FDG PET/CT) is a mainstay of oncologic imaging. PET/CT imaging is well-tolerated and therefore has become a powerful tool for the diagnosis, staging and monitoring of many metabolically-active cancers. However, ^18^F-FDG PET/CT imaging is not routinely used for detecting prostate cancer for both biological and technical reasons. Firstly, glucose uptake in well-differentiated prostatic adenocarcinoma is less avid than in many other cancers due to low glycolytic activity\[[@B1]\]. Secondly, urinary excretion of ^18^F-FDG in the bladder and urethra can mask pathological uptake in the adjacent prostate. Thirdly, there is a large overlap in ^18^F-FDG uptake between malignant disease, benign hyperplasia and inflammation of the prostate\[[@B1]\].

In men undergoing ^18^F-FDG PET/CT for unrelated reasons, incidental prostatic uptake is found in 0.6%-2.8% of studies\[[@B1]-[@B5]\]. Although this is a small percentage of cases, it affects a large number of men given the growing number of PET/CT studies performed per year: 50000 annually in the UK and 2 million annually in the United States\[[@B6],[@B7]\]. The significance of such incidental uptake, together with the need for further investigation, is both uncertain and controversial.

A previous meta-analysis of prostatic uptake on ^18^F-FDG PET/CT imaging showed that PET/CT cannot reliably differentiate benign from malignant disease, although only a small percentage of these patients underwent a definitive biopsy\[[@B8]\]. The published positive predictive value of ^18^F-FDG uptake for detecting prostate cancer ranges between 30% (in a low-risk population of men with bladder cancer undergoing radical prostatectomy) to 65% \[in a high-risk population of men undergoing prostate magnetic resonance imaging (MRI)\]\[[@B9],[@B10]\]. Some studies argue that the positive predictive value is increased if ^18^F-FDG uptake shows a high SUV~max~, the lesion is in a peripheral location and the CT demonstrates a lack of calcification\[[@B11]-[@B13]\]. However, these features all show considerable overlap between malignant and benign disease.

Serum prostate-specific antigen (PSA), multiparametric prostate magnetic resonance imaging (mpMRI) and prostate biopsy can be used to investigate incidental prostatic ^18^F-FDG uptake to determine if the patient has significant prostate cancer\[[@B5],[@B9]\]. However, there is no consensus on the management of patients with incidental prostatic ^18^F-FDG uptake\[[@B9]\].

In order to better understand the significance of incidental prostatic ^18^F-FDG uptake, we investigated both the correlation of prostatic ^18^F-FDG uptake with findings from MRI and histopathology, and the impact on patient management of reporting increased ^18^F-FDG uptake in the prostate.

MATERIALS AND METHODS
=====================

Study design and patient population
-----------------------------------

This single-institution retrospective study was approved locally, with the need for informed consent for data analysis waived. The hospital radiology database was searched to identify a total of 2846 ^18^F-FDG PET/CT studies performed on male patients in the period January 2010 to September 2015. For the first part of the study, 23 eligible men were identified who had both a prostate MRI and an ^18^F-FDG PET/CT study. 15 of these men had prostate adenocarcinoma on ultrasound-guided biopsy or MRI/ultrasound fusion biopsy. Five men were excluded (the prostate cancer was treated prior to undergoing PET/CT in 4 patients, and one patient had \> 4 years between MRI and PET/CT). For the second part of the study, the ^18^F-FDG PET/CT reports were searched to identify patients with incidentally reported focal prostatic ^18^F-FDG uptake. Patient records were examined for details of follow-up investigations and management. Two cases were included in both the first and second parts of the study.

MRI and ^18^F-FDG PET/CT analysis
---------------------------------

A proprietary workstation and software (Volume Viewer, Advantage Workstation, GE Healthcare, Milwaukee, WI, United States) were used to review the ^18^F-FDG PET/CT images. The prostate was divided into six sectors: Left and right sides at the apex, mid-zone and base of the gland. Standardised uptake values (SUV) in each sector were measured by an investigator who was blinded to the MRI and histopathological findings. A threshold of 75% of the SUV~max~ was used to calculate the SUV~mean~\[[@B14]\].

MRI reports were used to identify the prostatic sectors that were suspicious for tumour. Histopathology reports were used to identify the prostatic lobe(s) in which cancer had been detected. Sectorial analysis could not be performed for patients with no tumour focus on MRI, or bilateral tumour on histopathology (Figure [1](#F1){ref-type="fig"}).

![Flowchart showing inclusion and exclusion criteria for selection of cases for sector-based analysis.](WJR-9-350-g001){#F1}

Age-matched controls undergoing ^18^F-FDG PET/CT but without prostate cancer were randomly selected for each case from PET/CT studies recently undertaken in the department; two controls for each case were acquired. Age matching within 18 mo was used as the criterion, and patients with a known tumour close to the prostate were excluded.

Statistical analysis
--------------------

A paired two-tailed student's *t-*test was used to compare the ^18^F-FDG uptake within suspicious or malignant sectors, with that in the remaining prostate for each individual patient. A paired two-tailed student's *t-*test was also used to compare prostatic ^18^F-FDG uptake in patients with that from the controls. A one-way ANOVA was used to compare prostatic ^18^F-FDG uptake between histopathological subgroups. Statistical analyses were performed using GraphPad Prism version 6.00 (GraphPad Software, La Jolla, CA, United States).

RESULTS
=======

Eighteen patients who had both ^18^F-FDG PET/CT and prostate MRI studies were included in the first part of the study. The median age was 72 years, median PSA was 7.30 ng/mL and median time difference between the ^18^F-FDG PET/CT and the prostate MRI was 11.5 mo. See Table [1](#T1){ref-type="table"} for patient characteristics.

###### 

Characteristics of patients who had both ^18^F-labelled fluorodeoxyglucose positron emission tomography/computed tomography and prostate magnetic resonance imaging studies

  **Age** **(yr)**   **MRI before or after PET/CT?**   **18F-FDG PET/CT** **indication**    **Prostate SUVmax**   **Prostate MRI indication**             **MRI result**                **PSA (ng/mL)**   **Biopsy result**
  ------------------ --------------------------------- ------------------------------------ --------------------- --------------------------------------- ----------------------------- ----------------- ----------------------
  73                 2 mo before                       Bone metastases (prostate primary)   3.4                   Negative TRUS biopsy                    T2aNxMx                       20.8              Gleason 4 + 5 = 9
  72                 11 mo after                       Non-Hodgkin lymphoma                 2.7                   Elevated PSA, negative TRUS biopsy      T2aNxMx                       8.8               Gleason 5 + 3 = 8
  62                 3 mo after                        Cancer of unknown primary            3.9                   Prostate cancer staging                 T3bNxMx                       37                Gleason 4 + 3 = 7
  75                 46 mo after                       Head and neck cancer                 3.4                   Active surveillance                     T1NxMx                        2.28              Gleason 4 + 3 = 7
  76                 6 mo before                       Gastrointestinal stromal tumour      3                     Elevated PSA, negative TRUS biopsy      T2bNxMx                       150               Gleason 3 + 4 = 7
  79                 22 mo after                       Non-Hodgkin lymphoma                 2.9                   Elevated PSA                            T2aNxMx                       5.4               Gleason 3 + 4 = 7
  66                 30 mo after                       Non-Hodgkin lymphoma                 3.1                   Active surveillance                     T2cNxMx                       4.8               Gleason 3 + 4 = 7
  73                 26 mo after                       Oesophageal cancer                   2.4                   Active surveillance                     T2cNxMx                       7.8               Gleason 3 + 3 = 6
  68                 18 mo after                       Cancer of unknown primary            3.9                   Elevated PSA                            T2aNxMx                       6.1               Gleason 3 + 3 = 6
  74                 5 mo before                       Oesophageal cancer                   3.9                   Elevated PSA                            T1NxMx                        7.3               Gleason 3 + 3 = 6
  68                 5 mo before                       Hodgkin lymphoma                     9.9                   Elevated PSA, negative biopsy           No focus of tumour            4.7               High-grade PIN
  65                 39 mo before                      Colorectal cancer                    5.2                   Elevated PSA, negative TRUS biopsy      No focus of tumour            8.6               High-grade PIN
  76                 34 mo before                      Non-Hodgkin lymphoma                 4.2                   Elevated PSA                            Suspicious foci bilaterally   15                Benign
  67                 4 mo before                       Non-Hodgkin lymphoma                 4.1                   Incidental prostatic 18F-FDG uptake     Suspicious foci bilaterally   5.5               Benign
  72                 16 mo after                       Pyrexia of unknown origin            2.7                   Chronic urinary infection               Likely prostatitis            Not done          Biopsy not performed
  78                 1 mo after                        Non-Hodgkin lymphoma                 3.1                   Elevated PSA                            No focus of tumour            11.4              Biopsy not performed
  61                 12 mo after                       Lung nodule                          5.2                   Elevated PSA, positive family history   No focus of tumour            4.5               Biopsy not performed
  68                 7 mo after                        Colorectal cancer                    8.8                   Incidental prostatic ^18^F-FDG uptake   No focus of tumour            3                 Biopsy not performed

SUV: Standardised uptake value, PSA: Prostate specific antigen, TRUS: Transrectal ultrasound.

There was a trend for a higher ^18^F-FDG uptake in prostatic sectors shown to be suspicious on MRI or malignant on histopathology, compared to those in the remainder of the prostate, but this was not statistically significant (Figure [2](#F2){ref-type="fig"}). There was no significant difference in ^18^F-FDG uptake between cases with prostate cancer and age-matched controls undergoing PET/CT who did not have prostate cancer. Patients were classified into the following subgroups according to histopathology findings: biopsy not performed (*n* = 4), benign biopsy or high-grade prostatic intraepithelial neoplasia (PIN) (n = 4), low-grade prostate cancer with Gleason score ≤ 3 + 4 (*n* = 6), and high-grade prostate cancer with Gleason score ≥ 4 + 3 (*n* = 4). ^18^F-FDG uptake was not significantly different between subgroups; we therefore found no correlation between prostatic ^18^F-FDG uptake and the presence or grade of tumour confirmed on histopathology. Figure [3](#F3){ref-type="fig"} illustrates a representative case of a 70-year-old man with high-grade prostate cancer that showed no uptake on PET/CT. See Table [2](#T2){ref-type="table"} for mean values of SUV~max~ and SUV~mean~ derived from sectorial, case-control and subgroup analysis.

###### 

Sectorial analysis, case-control analysis and subgroup analysis showed no significant difference in ^18^F-labelled fluorodeoxyglucose uptake

                                                       **Mean SUVmax**   **Mean** **SUVmean**
  ---------------------------------------------------- ----------------- ----------------------
  Sectorial analysis                                                     
  MRI - normal prostatic sectors                       3.02              1.74
  MRI - suspicious prostatic sectors                   3.1               1.89
  Histopathology - benign prostatic lobe               2.86              1.79
  Histopathology - malignant prostatic lobe            3.13              1.82
  Case-control analysis                                                  
  Age-matched controls                                 3.09              1.83
  Cases with prostate cancer                           3.26              1.81
  Subgroup analysis                                                      
  Biopsy not performed                                 4.95              1.91
  Benign disease and high-grade PIN                    5.85              2.86
  Low-grade prostate cancer (Gleason ≤ 3 + 4)          3.2               1.83
  High-grade prostate cancer (Gleason score ≥ 4 + 3)   3.35              1.78

SUV: Standardised uptake value, PIN: Prostatic intraepithelial neoplasia.

![Sectorial analysis comparing ^18^F-labelled fluorodeoxyglucose uptake in sectors found to be suspicious on magnetic resonance imaging or malignant on histopathology with ^18^F-labelled fluorodeoxyglucose uptake in the remaining sectors. Mean values and standard deviations have been shown.](WJR-9-350-g002){#F2}

![High-grade prostate cancer showing no increased uptake on positron emission tomography/computed tomography in a 73-year-old man. A, B: Prostate MRI performed for raised PSA (19 ng/mL) showed a high probability lesion in the right apex transition zone (arrow in A) with matching restricted diffusion on the ADC map (B). Subsequent targeted transperineal biopsy confirmed Gleason 4 + 5 disease in 40% of cores; C, D: PET/CT performed after a two-month interval and no intervening treatment showed no focal uptake in this region shown as both fused PET/CT imaging (C) and PET alone (D). PET/CT: Positron emission tomography/computed tomography; MRI: Magnetic resonance imaging; ADC: Apparent diffusion co-efficient; PSA: Prostate specific antigen.](WJR-9-350-g003){#F3}

For the second part of the study, 2846 male patients undergoing ^18^F-FDG PET/CT over a 5-year period were followed-up. 46 men (1.6%) had an incidental and unexplained finding of elevated prostatic ^18^F-FDG uptake. 18 (0.6%) of these patients underwent further investigation. They had a median age of 68 years, median prostatic SUV~max~ of 7.80 and median PSA of 3.04 ng/mL. See Table [3](#T3){ref-type="table"} for patient characteristics.

###### 

Characteristics of patients in whom elevated prostatic ^18^F-labelled fluorodeoxyglucose uptake was investigated

  **Age (yr)**      **^18^F-FDG PET/CT indication**           **Prostate SUVmax**   **PSA (ng/mL)**   **Urology referral made**     **Urology outcome**
  ----------------- ----------------------------------------- --------------------- ----------------- ----------------------------- --------------------------
  68                Adrenal nodule                            10.4                  3                 Yes                           MRI - no suspicious foci
  77                Lung nodule                               4.5                   2.78              Yes                           Biopsy - high-grade PIN
  67                Non-Hodgkin lymphoma                      4.5                   5.5               Yes                           MRI - suspicious foci
  Biopsy - benign                                                                                                                   
  68                Colorectal cancer                         5.9                   3.04              Yes                           PSA monitoring
  58                Colorectal cancer                         7.6                   1.38              Yes                           PSA monitoring
  64                Non-Hodgkin lymphoma                      5.4                   1.84              Yes                           PSA monitoring
  58                Non-Hodgkin lymphoma                      19.9                  7.44              Yes                           PSA monitoring
  81                Cholangiocarcinoma                        10.3                  18                Yes                           Lost to follow up
  75                Hepatic metastases (colorectal primary)   8                     \-                Yes                           Lost to follow up
  61                Colorectal cancer                         14                    1.47              No - PSA normal               
  55                Paraneoplastic syndrome                   4.8                   0.62              No - PSA normal               
  61                Non-Hodgkin lymphoma                      5.8                   2.85              No - PSA normal               
  68                Gastrointestinal stromal tumour           13.2                  1.48              No - PSA normal               
  71                Hepatic metastases (colorectal primary)   9.2                   4.9               No - palliative care          
  87                Oesophageal cancer                        5.3                   11.86             No - palliative care          
  82                Colorectal cancer                         15.4                  3.85              No - palliative care          
  35                Hodgkin lymphoma                          11.8                  3.04              No - suspected prostatitis    
  71                Oesophageal cancer                        7.3                   4.58              No - likely urethral uptake   

SUV: Standardised uptake value; PSA: Prostate specific antigen; PIN: Prostatic intraepithelial neoplasia.

Of these 18 men, 9 (0.3%) were referred to urology. Two men had a prostate biopsy, which showed benign disease and high-grade PIN respectively (Figure [4](#F4){ref-type="fig"}). No cases of prostate cancer were diagnosed in the 5-year period. See Figure [5](#F5){ref-type="fig"} for more detailed clinical outcomes.

![Incidental prostatic ^18^F-labelled fluorodeoxyglucose uptake in a 67-year-old patient with Stage IV diffuse large B-cell lymphoma. A, B: Focal uptake in the posterior right peripheral zone of the prostate at the level of the mid-gland as demonstrated on PET (A) and fused PET/CT (B); SUVmax = 4.5; C-E: Prostate MRI shows non-specific geographical intermediate signal on T2-weighted imaging (C), but with no matching restricted diffusion on b-1400 diffusion-weighted images (D) or ADC maps (E). The MRI findings are low probability for tumour. Subsequent transrectal ultrasound-guided biopsy showed no cancer. PET/CT: Positron emission tomography/computed tomography; MRI: Magnetic resonance imaging; ADC: Apparent diffusion co-efficient.](WJR-9-350-g004){#F4}

![Flowchart showing clinical outcomes in patients with elevated prostatic ^18^F-labelled fluorodeoxyglucose uptake.](WJR-9-350-g005){#F5}

DISCUSSION
==========

Prostate cancer is the commonest male cancer\[[@B15]\]. There is therefore a potentially high incidence of synchronous prostatic tumour in patients undergoing ^18^F-FDG PET/CT for other indications. However, PET/CT lacks specificity and sensitivity for primary detection of prostate cancer; consequently it is unclear how patients with incidental tracer uptake in the prostate should be managed. Our study has shown that focal ^18^F-FDG uptake is not indicative of prostate cancer in this cohort, with SUV~mean~ and SUV~max~ values significantly overlapping between malignant and benign conditions, and that the reporting of incidental prostatic uptake did not affect subsequent clinical management of any patient in our institute over a 5-year period.

Sector-based analysis showed that, in individual patients, malignant prostatic sectors had a trend to higher ^18^F-FDG uptake than benign sectors. However, this difference was not statistically significant and total prostate ^18^F-FDG uptake in men with prostate cancer was comparable to that from age-matched controls. Comparison of ^18^F-FDG uptake across patient subgroups showed no correlation between ^18^F-FDG uptake and histopathological findings. Although some authors have suggested that ^18^F-FDG uptake weakly correlates with Gleason score, the small numbers in our study did not demonstrate this finding\[[@B9],[@B16]\]. In fact, we observed a higher SUV~max~ and SUV~mean~ in patients with no biopsy, benign biopsy or high grade PIN than in patients with prostate cancer. This may be partially explained by increased ^18^F-FDG uptake in prostatitis, where there is also increased glucose uptake within the inflammatory tissue\[[@B17]\].

Incidental and unexplained prostate uptake was found in 1.6% of all ^18^F-FDG PET/CT studies in male patients, which is comparable to the rate reported previously\[[@B3]-[@B5]\]. These patients had a median SUV~max~ of 7.8, which is suspicious for tumour; other authors have suggested an SUV~max~ greater than 6.0 should be considered as a cut-off value for high-grade prostate cancer\[[@B9]\]. Only 40% of patients with incidental and unexplained prostatic uptake were investigated with a serum PSA. Twenty percent of patients were referred to a urologist, and only one-third of these patients underwent further investigation with either biopsy or MRI. This may reflect the fact that the existing cancer diagnosis is the primary factor in determining clinical prognosis, and that the subsequent detection of prostate cancer would not significantly affect patient management due to unsuitability for radical therapy. Another possibility is a reluctance to perform a transrectal prostate biopsy in patients undergoing chemotherapy due to the risk of sepsis. In some patients, incidental prostatic uptake was not investigated for different reasons, *e.g*., uptake was thought to represent tracer in the urethra upon review (Figure [6](#F6){ref-type="fig"}), or uptake resolved on repeat PET/CT (Figure [7](#F7){ref-type="fig"}). Ultimately over a 5-year period in our centre, involving nearly three thousand ^18^F-FDG PET/CT studies, no change in patient management occurred as a result of an incidental finding of elevated prostatic ^18^F-FDG uptake. Therefore, our retrospective study questions the need to investigate incidental prostatic uptake of ^18^F-FDG in men undergoing PET/CT.

![Midline uptake on ^18^F-labelled fluorodeoxyglucose positron emission tomography/computed tomography in a 71-year-old man with oesophageal carcinoma and serum prostate specific antigen of 4.58 ng/mL. A, B: Fused PET/CT and PET-only imaging shows focal uptake in the midline of the prostate (arrowed). The uptake was considered to be tracer in the urethra given its anatomical location. PET/CT: Positron emission tomography/computed tomography.](WJR-9-350-g006){#F6}

![Resolving focal prostatic uptake in a 61-year-old man with Stage IV high-grade non-Hodgkin's lymphoma and serum prostate-specific antigen of 2.85 ng/mL. A: Fused PET/CT imaging performed after 2 cycles of chemotherapy shows focal uptake (arrowed) in the left side of the prostate at the level of the midgland on fused PET/CT; B: Repeat PET/CT performed 4 mo later following completing of 6 cycles of chemotherapy demonstrates resolution of this focal uptake. PET/CT: Positron emission tomography/computed tomography.](WJR-9-350-g007){#F7}

Our study has some limitations. Firstly, as a retrospective study our population consisted of patients who underwent ^18^F-FDG PET/CT primarily for other malignancies, and therefore the time difference between PET/CT and MRI was long in some cases (up to 46 mo). This timescale is similar to previously reported retrospective studies and given that the natural history of prostate cancer is one of a slow-growing tumour, most prostate cancers will be present for years before clinical presentation\[[@B10],[@B18]\]. Secondly, the number of eligible patients in our study was small. Thirdly, patients in our study had ultrasound-guided biopsy or MRI/ultrasound fusion biopsy, which are less sensitive in detecting prostate cancer than whole-mount histology derived from prostatectomy samples.

In conclusion, ^18^F-FDG uptake has low clinical utility in distinguishing benign and malignant prostatic disease. Reporting incidental prostatic uptake did not affect subsequent patient management or clinical outcomes in this cohort of patients. This study suggests there may be little benefit in investigating incidental elevated prostatic ^18^F-FDG uptake on PET/CT which should be addressed with future large prospective studies.

COMMENTS
========

Background
----------

^18^F-labelled fluorodeoxyglucose (^18^F-FDG) uptake on positron emission tomography/computed tomography (PET/CT) is used extensively in the diagnosis, staging and monitoring of many cancers. Incidental elevated prostatic ^18^F-FDG uptake is found in a significant proportion of men undergoing PET/CT for unrelated reasons. ^18^F-FDG PET/CT is not routinely used in prostate cancer because of the relatively low metabolic activity of prostate cancer, the proximity to tracer in the urethra and the presence of significant ^18^F-FDG uptake in benign and inflammatory prostatic disease.

Research frontiers
------------------

The significance of incidental prostatic uptake, together with the need for further investigation, is unclear.

Innovations and breakthroughs
-----------------------------

The results suggest that incidental prostatic uptake has no significant correlation with prostate magnetic resonance imaging or biopsy findings. In a cohort of nearly 3000 men over 5 years, reporting incidental prostatic ^18^F-FDG uptake did not alter patient management or clinical outcomes.

Applications
------------

The results suggest there is little benefit in investigating incidental elevated prostatic ^18^F-FDG uptake.

Peer-review
-----------

This is an interesting study which investigates the clinical significance of incidental FDG uptake. Although the number of eligible patients was small, this is an well written retrospective study.
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